4/A: Beta Bionics CMO Corrects Stock Option Grant

Beta Bionics' Chief Medical Officer, Steven Jon Russell, filed an amended Form 4 to correct the number of shares in a recent employee stock option grant.

Summary

• The filing is an amendment (Form 4/A) to a previously submitted Statement of Changes in Beneficial Ownership.
• The reporting person is Steven Jon Russell, the Chief Medical Officer of Beta Bionics, Inc. (BBNX).
• The purpose of the amendment is to correct the number of shares underlying an employee stock option grant.
• On February 27, 2026, Mr. Russell acquired 91,520 employee stock options.
• These options have an exercise price of $12.63 per share.
• The shares subject to this option will vest in 36 equal monthly installments, commencing on March 1, 2026.
• The expiration date for these employee stock options is February 26, 2036.
• Following this reported transaction, Mr. Russell beneficially owns 91,520 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral administrative update, with a slight positive tilt due to the insider's acquisition of a significant option grant, aligning interests, but the correction itself is not a material event.

Positives

• The Chief Medical Officer acquired a significant grant of 91,520 employee stock options, aligning his long-term interests with the company's performance and shareholder value.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule of the granted options.

Management Comments

• "The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026."

Industry Context

StockSavvy.ai notes that insider option grants are a common form of executive compensation in the biotechnology and medical device industries, serving to align management incentives with long-term shareholder value. The correction of a filing is a routine administrative process.

Comparison to Industry Standards

• StockSavvy.ai observes that option grants with multi-year vesting schedules, such as the 36-month period mentioned, are standard practice across various industries, including biotechnology, to promote long-term retention and performance. For example, similar vesting schedules are commonly seen at companies like Medtronic (MDT) or Dexcom (DXCM) for executive equity awards.

Stakeholder Impact

• Shareholders: The correction ensures accurate public record of insider holdings. The option grant itself aligns the Chief Medical Officer's interests with shareholder value over the vesting period, potentially incentivizing long-term performance.

Next Steps

• The 91,520 shares subject to the option will vest in 36 equal monthly installments, commencing March 1, 2026.

Key Dates

Recommendation

This filing is an administrative correction to an insider's option grant and does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It merely clarifies an existing compensation detail.

Keywords

Beta Bionics, BBNX, Form 4/A, Insider Transaction, Stock Option, Equity Compensation, Chief Medical Officer, Steven Jon Russell, Vesting